ARCHIVES

Long-Term Effect Of One Phase III Trial: Benefit For Thousands Of Patients

This article is from The Cancer Letter archive.

Vol. 32 No. 11 | November 27, 2009

Download PDF Visit The Full Archive

Related Articles

FDA Approves Velcade For Treatment Of Refractory Multiple Myeloma

May 30, 2003

Also in this 8-page issue: NCI, FDA open Web site for adverse event reporting.

April 16, 2004

CMS to delay final rule publication for oncology.

October 31, 2003

In Brief: Mary-Claire King Named Disney Professor By Cancer Society; Date Corrected In Article

July 1, 1994

HHS Group To Study Policies Affecting Academic Centers

June 20, 1997

Docetaxel, Oxaliplatin Active Against Esophageal Cancer

June 30, 2006